Glenmark to Begin Phase 3 Trial of Favipiravir and Umifenovir for COVID-19

Glenmark will conduct a phase 3 trial in India, testing the efficacy of antivirals favipiravir and umifenovir for the treatment of COVID-19.

The trial will examine if early administration of the drug combination will enhance efficacy in 158 hospitalized patients with moderate COVID-19, who will be randomized to receive either favipiravir with or without umifenovir along with the standard of care.

The company is also conducting phase 3 trials of favipiravir as a COVID-19 monotherapy in 150 patients from nine hospitals across India.